Celsion is a clinical stage biotechnology company. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for the treatment of ovarian cancer. ThermoDox®, Co.'s proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications, which is being managed though Co.'s wholly owned subsidiary, Celsion GmbH. Additionally, Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. We show 21 historical shares outstanding datapoints in our CLSN shares outstanding history coverage, used to compute CLSN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CLSN market cap history over the course of time is important for investors
interested in comparing CLSN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CLSN versus a peer is one thing; comparing
CLSN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CLSN can fluctuate over the course of history.
With this page we aim to empower investors researching CLSN by allowing them to research the CLSN market cap history. |
Free CLSN Email Alerts:
Video: The Importance of Market Cap
